Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

The double-edged sword of COX-2 selective NSAIDs.

Wright JM.

CMAJ. 2002 Nov 12;167(10):1131-7. Review.

2.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
3.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
5.

Are rofecoxib and celecoxib safer NSAIDS?

[No authors listed]

Drug Ther Bull. 2000 Nov;38(11):81-6. Review.

PMID:
11138599
6.

Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.

Fung HB, Kirschenbaum HL.

Clin Ther. 1999 Jul;21(7):1131-57. Review.

PMID:
10463513
7.

[COX-2 inhibitors--one step forward and two steps back].

Evensen S, Spigset O, Slørdal L.

Tidsskr Nor Laegeforen. 2005 Apr 7;125(7):875-8. Review. Norwegian.

8.

An evidence-based evaluation of the gastrointestinal safety of coxibs.

Bombardier C.

Am J Cardiol. 2002 Mar 21;89(6A):3D-9D. Review.

PMID:
11909555
9.

Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.

Mallen SR, Essex MN, Zhang R.

Curr Med Res Opin. 2011 Jul;27(7):1359-66. doi: 10.1185/03007995.2011.581274. Epub 2011 May 12. Review.

PMID:
21561397
10.

Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?

Laine L.

J Pain Symptom Manage. 2002 Apr;23(4 Suppl):S5-10; discussion S11-4. Review.

PMID:
11992743
11.

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.

Moore RA, Derry S, Makinson GT, McQuay HJ.

Arthritis Res Ther. 2005;7(3):R644-65. Epub 2005 Mar 24. Review. Erratum in: Arthritis Res Ther. 2006;8(1):401.

12.

COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.

Hochberg MC.

Curr Top Med Chem. 2005;5(5):443-8. Review.

PMID:
15974939
13.

Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.

Goldenberg MM.

Clin Ther. 1999 Sep;21(9):1497-513; discussion 1427-8. Review.

PMID:
10509845
14.

COX-2 inhibition and thrombotic tendency: a need for surveillance.

Cleland LG, James MJ, Stamp LK, Penglis PS.

Med J Aust. 2001 Aug 20;175(4):214-7. Review.

PMID:
11587283
15.

COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?

Simon LS.

Gastroenterol Clin North Am. 2001 Dec;30(4):1011-25, viii. Review.

PMID:
11764530
16.
17.

[Clinical pharmacology of the selective COX-2 inhibitors].

Burian M, Geisslinger G.

Orthopade. 2003 Dec;32(12):1078-87. Review. German.

PMID:
14655004
18.
20.

A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.

Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL.

Pharmacoeconomics. 2001;19 Suppl 1:33-47. Review.

PMID:
11280104
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk